Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for Preventing Myelosuppression in Thoracic Malignancies
NCT07205536Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of mecapegfilgrastim in myelosuppression, neutropenia, sponsored by Affiliated Hospital of Nantong University. Started Aug 2025; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
myelosuppressionneutropenia
Beyond the preview
Go deeper on NCT07205536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205536.